China Life Private Equity

China Life Private Equity is a private equity firm established in 2016 and located in Beijing, China. The firm specializes in equity investments, focusing on sectors such as life sciences, medical technology, healthcare services, and digital health. Through its investments, China Life Private Equity aims to support the growth and development of innovative companies within these industries.

Wan Yiqing

President

Leidi Zhang

Managing Director

25 past transactions

SJ Semi

Venture Round in 2024
SJ Semi is a MEOL foundry focused on front-end wafer manufacturing and quality systems. The company specializes in bumping, Cu pillar, RDL, and testing services for 12" wafers while investing in R&D for fan-out, TSV, interposer, and 3D technologies. With over a decade of experience, SJ Semi aims to support advancements in the semiconductor market.

Autolink

Series D in 2024
Autolink is involved in the automotive intelligence industry. They create a product portfolio centered on vehicle intelligence, SOA architecture, and multi-domain integration based on the central controller. They offer a single product that supports instrumentation, central control, copilot, rear seat entertainment, air conditioning control, the HUD, and surround view.

Xindi Digital Engineering System

Series D in 2024
Xindi Digital Engineering System specializes in the development of commercial software products for computer-aided design (CAD), focusing on 3D technology. The company creates CAD content compatible with a variety of systems, including AutoCAD, SolidWorks, CATIA, UG, Pro/E, Inventor, Solid Edge, Geomagic, Maya, and 3D Studio Max. By providing these solutions, Xindi enables manufacturing enterprises to efficiently establish comprehensive digital product development and design systems.

Weikaier Pharmaceutical Technology

Series C in 2024
Weikaier Pharmaceutical provides R&D of innovative drugs, transfer of generic drug technology, the production and sales of pharmaceuticals.

Astronergy

Series C in 2023
Astronergy is a manufacturing firm that specializes in the research, development, and production of solar modules to generate clean energy. Established in 2006, it is recognized as the first large-scale producer of high-efficiency thin film photovoltaic (PV) modules in mainland China. The company is a trusted provider of both monocrystalline and polycrystalline PV modules and focuses on creating high-efficiency crystalline silicon solar cells and modules. These products are designed for various applications, including utility-scale power stations, commercial and industrial PV systems, and residential PV systems. Astronergy aims to deliver high-quality and high-performance photovoltaic solutions to support the global transition to renewable energy.

Xindi Digital Engineering System

Series D in 2023
Xindi Digital Engineering System specializes in the development of commercial software products for computer-aided design (CAD), focusing on 3D technology. The company creates CAD content compatible with a variety of systems, including AutoCAD, SolidWorks, CATIA, UG, Pro/E, Inventor, Solid Edge, Geomagic, Maya, and 3D Studio Max. By providing these solutions, Xindi enables manufacturing enterprises to efficiently establish comprehensive digital product development and design systems.

Sunwoda Electric Vehicle Battery

Series B in 2023
Sunwoda Electric Vehicle Batter provides electric vehicle battery pack solutions for new energy vehicle companies through advanced lithium battery integration technology. They built the BMS with independent intellectual property rights by dedicating their entire ability to the R&D and manufacturing of electric car battery systems, and they also built up automatic production lines for cell sorting, modules, and battery packs.

Care Medical

Series C in 2023
Care Medical is a membrane science platform that focuses on blood purification and biopharmaceuticals.

Yingke Biopharmaceutical

Series B in 2023
Yingke Biopharmaceutical operates as a high-tech biopharmaceutical enterprise integrating R&D, production and sales.

VJTBio

Series C in 2023
VJTBio is a biopharmaceutical company specializing in the high-end animal protein pharmaceutical market. It develops innovative biopharmaceuticals aimed at enhancing reproductive and immune health in animals. Utilizing genetic recombination techniques, the company focuses on solutions for animal reproduction, disease prevention, and pet health. In addition to its research and development efforts, VJTBio is involved in the production and sales of advanced treatments for animal health, offering clinical testing and technical services to the biopharmaceutical industry and medical professionals.

Svision

Series C in 2023
Svision is a healthcare start-up that develops and produces high-end ophthalmic imaging equipment.

Fushoukang

Series C in 2022
Shanghai Fushoukang Rehabilitative Home Nursing Services specializes in in-home rehabilitation and nursing care for the elderly, as well as individuals who are weak, sick, or disabled. Founded in 2011 and headquartered in Shanghai, the company offers a range of services including home care, community care, nursing care, and bathing assistance. By focusing on the needs of vulnerable populations, Fushoukang aims to enhance the quality of life for its clients through personalized care in the comfort of their own homes.

Maxvax Health

Series B in 2022
Maxvax Health is a biotechnology company focused on the development and commercialization of innovative vaccines. The company specializes in vaccine technology targeting viral diseases, including rotavirus, shingles, and herpes. By advancing these vaccines, Maxvax Health aims to enhance treatment options for healthcare professionals and improve patient outcomes. Through its efforts in vaccine development, the company seeks to address significant health challenges posed by viral infections.

Maxvax Health

Series B in 2022
Maxvax Health is a biotechnology company focused on the development and commercialization of innovative vaccines. The company specializes in vaccine technology targeting viral diseases, including rotavirus, shingles, and herpes. By advancing these vaccines, Maxvax Health aims to enhance treatment options for healthcare professionals and improve patient outcomes. Through its efforts in vaccine development, the company seeks to address significant health challenges posed by viral infections.

HanBang Technology

Series C in 2022
HanBang Technology is a manufacturer and provider specializing in advanced 3D printing equipment, primarily targeting the aerospace and electronics industries. The company focuses on metal 3D printer machines and employs cutting-edge technologies, including selective laser melting and multi-laser additive technology, to deliver comprehensive application solutions. In addition to its strong emphasis on research and development, HanBang Technology integrates production and trade, positioning itself as a key player in the liquid chromatography sector. The company's expertise extends to machine delivery and installation, ensuring effective implementation of its innovative solutions in industrial applications.

METiS Therapeutics

Series B in 2022
METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.

Immunochina

Series D in 2021
ImmunoChina Pharmaceuticals manufactures medical products. The Company produces cell injections, cell therapy drugs, and other products. ImmunoChina Pharmaceuticals also provides medical technology development, medical research, medical trial development, and other services.

Sinotau

Series D in 2021
SinoTau is a comprehensive solution provider in the pharmaceutical sector, focusing on both generic and innovative drugs. The company specializes in the early development of antibody biopharmaceuticals and produces advanced generic medications. It aims to address various therapeutic areas, including cardiovascular diseases, neurodegeneration, and tumors. SinoTau's expertise encompasses medicinal chemical synthesis, generic drug analysis, pharmaceutical preparations, and drug registration, supported by leading research in targeted drug development. The company leverages advanced diagnostic methods and monoclonal antibody technologies to enhance its offerings, positioning itself as a key player in the biotechnology industry.

GeneQuantum Healthcare

Series C in 2021
GeneQuantum Healthcare (Suzhou) Co., Ltd. is a high-tech company established in August 2013 in Suzhou Industrial Park, specializing in the research and development of innovative biotherapeutics. The company has developed a world-class bioconjugation technology platform that emphasizes the creation of next-generation anti-tumor Antibody-Drug-Conjugates (ADCs) with significant therapeutic potential. Utilizing a ligase-dependent conjugation platform, GeneQuantum enhances the therapeutic window for these drugs, allowing for advanced development in the field of oncology. The company is currently focused on advancing its ADC candidates toward Investigational New Drug (IND) filing in both the United States and China, while also expanding its product pipeline to address unmet medical needs in cancer treatment.

Vazyme Biotech

Series C in 2020
Vazyme Biotech Co., Ltd. is a biotechnology company founded in 2012 and based in Nanjing, China. The company specializes in the development and production of enzymes and antibodies, with applications in clinical diagnosis, molecular diagnostics, high-throughput sequencing, and life science research. Vazyme Biotech is dedicated to advancing its research and development capabilities, emphasizing functional proteins and polymer organic materials. Positioned in the National Economic and Technological Development Zone of Nanjing, the company leverages its strategic location and cutting-edge technology to innovate within the biotechnology sector.

OPM Biosciences

Corporate Round in 2020
OPM Biosciences is a biotechnology company based in Shanghai, specializing in the development and production of serum-free media for culturing animal cells. The company offers innovative cell culture solutions and provides comprehensive contract development and manufacturing organization (CDMO) services. OPM Biosciences aims to enhance the efficiency and effectiveness of cell culture processes, catering to the needs of various sectors within the biotechnology industry. Through its advanced technologies and expertise, OPM Biosciences supports the growth and scalability of its clients' projects, contributing to advancements in life sciences.

Harbour BioMed

Series B in 2018
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases. Established in 2016 with operations in Shanghai, Cambridge, and Rotterdam, the company leverages its proprietary transgenic mouse platforms to generate fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb), enabling the development of differentiated compounds such as bi-specific and multi-specific antibodies. Harbour BioMed collaborates strategically with various institutions and companies, including The Wistar Institute, WuXi Biologics, and Vir Biotechnology, to advance its pipeline of therapeutics targeting autoimmune diseases, dry eye disease, COVID-19, and other indications.

Wanka Online

Series C in 2018
Wanka Online Inc. is a technology company based in Beijing, China, that specializes in android-based content distribution services. Founded in 2014, the company connects businesses across various industries to China's extensive base of Android smartphone users. It operates through four main segments: mobile advertising services, online video distribution, game co-publishing, and software maintenance. The DAPG platform, a key offering, utilizes advanced technologies such as data mining and analytics to enable marketers to effectively target users and deliver personalized content through mobile applications. Wanka Online is particularly known for its mobile advertising services, which generate the majority of its revenue, positioning the company as a significant player in the mobile Internet market.

Asia Bioenergy Technologies Berhad

Venture Round in 2013
Asia Bioenergy Technologies Berhad (ABT) is a Malaysia-based technology incubation and investment holding company. The Company operates in four business segments: technology incubation, which comprises the main business segments; biofuel related products, which includes the sale of compounds for use in biofuel processes; information technology, which is engaged in the provision of information technology training and related services and equipment and corporate services, and biotechnology products, which is engaged in the provision of biotechnology products and services.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.